Now Available: Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
By: Fast Market Research, Inc.
 
April 28, 2012 - PRLog -- GlobalData, the industry analysis specialist, has released its new report, "Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Multiple Sclerosis market. The report identifies the key trends shaping and driving the global Multiple Sclerosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Multiple Sclerosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/381302_multiple_sclerosis_therapeutics_pipeline.aspx
------------------------------------------------------------

Scope

The report provides information on the key drivers and challenges of the Multiple Sclerosis market. Its scope includes -

* Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Multiple Sclerosis market revenues data from 2006 to 2011, forecast for eight years to 2019.
* Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
* Analysis of the current and future competition in the seven key countries Multiple Sclerosis market.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Multiple Sclerosis market.
* Analysis of key recent licensing and partnership agreements in Multiple Sclerosis market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
* Develop business strategies by understanding the trends shaping and driving the global Multiple Sclerosis market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Multiple Sclerosis market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
* Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
* What's the next big thing in the global Multiple Sclerosis market landscape? - Identify, understand and capitalize.

Companies Mentioned in this Report: Sanofi, Merck KGaA/Merck Serono, Biogen Idec, Teva Pharmaceutical Industries (Teva), Nuron Biotech, F. Hoffmann-La Roche (Roche), Teijin Pharma, Accentia Biopharmaceuticals, AB Science, Abbott

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Multiple Sclerosis Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Prevalence by Gender
2.2.3 Prevalence by Age Group
2.2.4 Prevalence by Disease Severity
2.2.5 Quality of Life (QoL)
2.2.6 Comorbidities in MS
2.2.7 Pharmaco-Economic Burden
2.3 Etiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Diagnostic Criteria:
2.6 Treatment and Management Pattern
2.6.1 Treatment for Acute Relapses of MS Symptoms
2.6.2 Treatment for Specific MS Symptoms
2.6.3 Treatment to Slow the Progression of MS (DMDs)
2.7 Rehabilitation
2.7.1 Physical Therapy
2.7.2 Occupational Therapy
2.7.3 Speech Therapy
2.8 Complementory and Alternative Therapy
2.9 Surgical Care
2.10 Referral Pathway
2.11 GlobalData Pipeline Report Guidance
3 Multiple Sclerosis Therapeutics - Market Characterization
3.1 Multiple Sclerosis Therapeutics Market Size (2006 - 2011) - Global
3.2 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - Global
3.3 Multiple Sclerosis Therapeutics Market Size (2006-2011) - The US
3.4 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - The US
3.5 Multiple Sclerosis Therapeutics Market Size (2006-2011) - France
3.6 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - France
3.7 Multiple Sclerosis Therapeutics Market Size (2006-2011) - Germany
3.8 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - Germany
3.9 Multiple Sclerosis Therapeutics Market Size (2006-2011) - Italy
3.10 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - Italy
3.11 Multiple Sclerosis Therapeutics Market Size (2006-2011) - Spain
3.12 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - Spain
3.13 Multiple Sclerosis Therapeutics Market Size (2006-2011) - The UK
3.14 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - The UK
3.15 Multiple Sclerosis Therapeutics Market Size (2006-2011) - Japan
3.16 Multiple Sclerosis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Multiple Sclerosis Therapeutics Market
3.17.1 Drivers for the Multiple Sclerosis Therapeutics Market
3.17.2 Barriers for the Multiple Sclerosis Therapeutics Market

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=3813...

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.  View more research from GlobalData at http://www.fastmr.com/catalog/publishers.aspx?pubid=1015
End
Source:Fast Market Research, Inc.
Email:***@fastmr.com Email Verified
Zip:01267
Tags:Sclerosis, Therapeutic, Pipeline, MS, 2011-2019, Clinical, Kol, Trial, Treatment, Drug
Industry:Medical
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share